I think that the comment by Nader that there are a few parties in the "data room" means a lot more than we realize. This data room phase is basically the due diligence part of reviewing partnerships. What they see in this data room is likely way more than what we know publicly.

I am sure there are HIV trial participants that have NASH and are showing positive response from being on Leronlimab. That is data that is more compelling than the animal studies. I think this is why Nader is confident that a partner will be picking up the trial process.